Lind Raises Seed Round to Build Intelligent Clinical Trial Infrastructure
Lind raised $5.5M in seed funding led by 8VC, Abstract Ventures, and Correlation Ventures to build the first trial, screening platform designed for health systems, not sponsors. Lind screens every patient against every open study nightly, surfacing EHR-native matches with evidence already mapped to eligibility criteria.
By Lind Team
San Francisco, CA — December 15, 2023 — Lind today announced it has raised $5.5 million in seed funding led by 8VC, Abstract Ventures, and Correlation Ventures. The capital will be used to build and deploy the first clinical trial screening platform designed for health systems.
The platform is built to screens every patient against every appropriate open study and surfaces matches directly inside the EHR. The goal is a platform that has no disease-area restriction. Coordinators see a prioritized list of candidates when they start their day, with the clinical evidence already mapped to eligibility criteria.
This design reflects a core belief: the health system, not the sponsor, should be at the center of clinical research operations. When a platform is built for the site, it can serve all trials, investigator-initiated, cooperative group, and industry-sponsored, without the conflicts of interest that come from sponsor-funded tools.
“Health systems run trials, but they’ve never had technology that works for them,” said Ognjen (Oggie) Nikolic, co-founder and CEO of Lind. “We’re building the infrastructure layer that makes clinical research a natural extension of patient care, not a side operation driven by sponsor outreach.”
Nikolic previously held roles at Google and GRAIL, where he built AI/ML products at scale, and at Betteromics. He studied Computer Engineering at the University of Waterloo. He co-founded Lind with Pranav Singh, who serves as CTO. Singh’s background spans engineering leadership at Illumina and GRAIL, as well as Upstart. He holds an MS in Computer Science from Georgia Tech and began his career at Medtronic Neurovascular.
“The technical challenge here is not matching, it’s matching at scale without creating work,” said Singh. “A platform that adds hours to a coordinator’s day will never get adopted. We designed Lind to run autonomously against the full trial landscape and deliver results that are immediately actionable.”